H.C. Wainwright analyst Edward White maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) today. The company’s shares opened today at $0.24.
White covers the Healthcare sector, focusing on stocks such as Valneva, Nyxoah, and Syndax Pharmaceuticals. According to TipRanks, White has an average return of -11.0% and a 32.33% success rate on recommended stocks.
Currently, the analyst consensus on 60 Degrees Pharmaceuticals, Inc. is a Moderate Buy with an average price target of $1.30.
The company has a one-year high of $8.65 and a one-year low of $0.22. Currently, 60 Degrees Pharmaceuticals, Inc. has an average volume of 238.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
60 Degrees Pharmaceuticals, Inc. (SXTP) Company Description:
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
Read More on SXTP:
